Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727871 | 0.84 | AURKA (0.34) | S1PR1S1PR5S1PR3CNR1 | |
| SCHEMBL17627108 | 0.80 | RORC (0.41) | RORCS1PR1S1PR5S1PR3SCN9A | |
| SCHEMBL401766 | 0.78 | P2RY12 (0.45) | RORCS1PR1S1PR5S1PR3SCN9A | |
| SCHEMBL1964065 | 0.78 | RORC (0.43) | RORCS1PR1S1PR5S1PR3SCN9A | |
| SCHEMBL1013088 | 0.77 | RORC (0.42) | RORCS1PR1S1PR5S1PR3SCN9A | |
| SCHEMBL404384 | 0.77 | RORC (0.45) | RORCS1PR1S1PR5S1PR3SCN9A | |
| SCHEMBL1963502 | 0.76 | PARP10 (0.44) | RORCS1PR1S1PR5S1PR3SCN9A | |
| SCHEMBL1725828 | 0.74 | KMT2A (0.43) | S1PR5S1PR3 | |
| SCHEMBL1965618 | 0.73 | S1PR1 (0.37) | RORCS1PR1S1PR5S1PR3SCN9A | |
| SCHEMBL1965620 | 0.73 | S1PR1 (0.37) | RORCS1PR1S1PR5S1PR3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | RORC 173/4885S1PR1 2/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.